Research Analysts Set Expectations for CRSP Q1 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of ($0.74) for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.63) EPS, FY2026 earnings at $3.95 EPS, FY2027 earnings at $5.51 EPS, FY2028 earnings at $9.80 EPS and FY2029 earnings at $45.40 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

Several other research analysts have also recently issued reports on CRSP. Stifel Nicolaus reduced their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday. Barclays raised their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Truist Financial upped their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America reduced their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $75.30.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $43.49 on Friday. The business has a fifty day moving average of $42.06 and a 200 day moving average of $46.25. The firm has a market capitalization of $3.71 billion, a price-to-earnings ratio of -15.37 and a beta of 1.67. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the business. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth $39,000. Western Pacific Wealth Management LP boosted its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics during the third quarter worth about $43,000. Finally, Eastern Bank acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at about $70,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.